Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Notwithstanding recent treatment advances in metastatic colorectal cancer (mCRC),
chemotherapy with a combination of a fluoropyrimidine and a folate agent, often 5 …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

A cancer tumour consists of thousands of genetic mutations. Even after advancement in
technology, the task of distinguishing genetic mutations, which act as driver for the growth of …

Colorectal cancer (CRC) is the second leading cause of cancer death in the world.
Immunotherapy using monoclonal antibodies, immune-checkpoint inhibitors, adoptive cell …

The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved
oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). Despite …

Since its introduction, the use of cetuximab in the treatment of head and neck squamous cell
carcinoma (HNSCC) has experienced an evolution. Currently, cetuximab associated with …

Upfront KRAS and NRAS gene testing ('RAS') is the standard of care for metastatic
colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) …

Background Unplanned subgroup analyses from several studies have suggested primary
tumor sidedness (PTS) as a potential prognostic and predictive parameter in metastatic …

Studies have shown that transcription factor activating enhancer binding protein 4 (TFAP4)
plays a vital role in multiple types of cancer; however, the TFAP4 expression profile is still …